search
Back to results

Diagnostic Performance of a New Bio-marker During Bacterial Sepsis (BACTIDIAG)

Primary Purpose

Sepsis

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
additional blood tubes
Sponsored by
Centre Hospitalier Universitaire de Nice
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Sepsis

Eligibility Criteria

18 Years - 95 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age> = 18 years
  • Patient hospitalized in ICU with a diagnosis of SIRS:
  • Temperatures above 38 ° C or below 36 ° C

At least one other criterion from:

  • Heart rate> 90 bpm
  • Respiratory rate above 20 breaths / min or PaCO2 <32 mmHg
  • Leukocytosis greater than or less than 4000/mm3 12000/m3

    • Patient admitted in intensive care for less than 12 hours
    • Patient does not preclude its participation in the study.

Exclusion Criteria:

  • No affiliation to a social security scheme (beneficiary or assignee)

Sites / Locations

  • Antibes hospital Center
  • Cannes Hospital
  • Draguignan Hospital
  • Frejus Hospital
  • CHU de Nice
  • Monaco princesse grace Hospital

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

additional blood tubes

Arm Description

Outcomes

Primary Outcome Measures

determine the AUC
determine the AUC of a test ( Bacti DIAG ) for the diagnosis of sepsis and sepsis Gram + Gram - relative to the composite gold standard . Two analyzes will be performed , one for the diagnosis of sepsis Gram + and to that of sepsis Gram . We describe below the analysis to be conducted on Gram + diagnosis , it will suffice to transpose the study of Gram

Secondary Outcome Measures

Full Information

First Posted
March 7, 2016
Last Updated
March 17, 2022
Sponsor
Centre Hospitalier Universitaire de Nice
Collaborators
Bio-Rad Laboratories
search

1. Study Identification

Unique Protocol Identification Number
NCT02721134
Brief Title
Diagnostic Performance of a New Bio-marker During Bacterial Sepsis
Acronym
BACTIDIAG
Official Title
Diagnostic Performance of a New Bio-marker During Bacterial Sepsis
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
March 2016 (Actual)
Primary Completion Date
May 2018 (Actual)
Study Completion Date
November 17, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Nice
Collaborators
Bio-Rad Laboratories

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Sepsis is a constant concern in ICU, frequent and severe, it requires early diagnosis and prompt implementation of the etiological treatment. The bacterial infections are the most common and are associated with high morbidity and mortality. Diagnosis is based on the detection of micro-organisms (bacteria) that can confirm the diagnosis and to tailor antibiotic treatments. Blood cultures are positive in 30-35% of cases and diagnosis is often based on a body of evidence that the use of biomarkers. No biomarkers (or even a combination of biomarkers) no evidence to confirm or refute the diagnosis of sepsis alone. During sepsis, gram + and gram - are circulating and often present in small amounts; they can be detected by sensitive and specific tools following a pretreatment of the blood sample (innovative technology Bacti-DIAG). The main objective of the multicentre study Bacti-DIAG-Rea is testing in prospectively, in a suspicious population resuscitation of sepsis, this new bacterial biomarker. Secondary objectives will assess whether Bacti-DIAG provides time and precision gain (gram + vs grams) in the patient's care including diagnosis and treatment. All ICU patients and with clinical criteria of Systemic Inflammatory Response Syndrome (SIRS) sepsis suspects will be included: in addition to the samples taken for routine care of the patient 4 tubes of whole blood will be collected 5mL. The definitive diagnosis of sepsis or SIRS be confirmed retrospectively by two independent experts blinded to Bacti-DIAG. The areas under the ROC curves for the detection of gram + and gram will be calculated and associated detection limits will be determined to meet the objectives of the study. It is planned to include 400 consecutive patients with SIRS criteria for sepsis 300-360 and analyze biometric and biological data based on the subsequent evolution of the patients. The care of patients will be blinded to the results of the new biomarker Bacti-DIAG

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
450 (Actual)

8. Arms, Groups, and Interventions

Arm Title
additional blood tubes
Arm Type
Other
Intervention Type
Other
Intervention Name(s)
additional blood tubes
Intervention Description
four whole blood tubes 5 ml (2 + EDTA tubes separating gel and dry tubes 2 + separating gel ) will be taken in order to assay more bacterial biomarkers on day 0 , J1, J2, J3 and J5
Primary Outcome Measure Information:
Title
determine the AUC
Description
determine the AUC of a test ( Bacti DIAG ) for the diagnosis of sepsis and sepsis Gram + Gram - relative to the composite gold standard . Two analyzes will be performed , one for the diagnosis of sepsis Gram + and to that of sepsis Gram . We describe below the analysis to be conducted on Gram + diagnosis , it will suffice to transpose the study of Gram
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
95 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age> = 18 years Patient hospitalized in ICU with a diagnosis of SIRS: Temperatures above 38 ° C or below 36 ° C At least one other criterion from: Heart rate> 90 bpm Respiratory rate above 20 breaths / min or PaCO2 <32 mmHg Leukocytosis greater than or less than 4000/mm3 12000/m3 Patient admitted in intensive care for less than 12 hours Patient does not preclude its participation in the study. Exclusion Criteria: No affiliation to a social security scheme (beneficiary or assignee)
Facility Information:
Facility Name
Antibes hospital Center
City
Antibes
ZIP/Postal Code
06600
Country
France
Facility Name
Cannes Hospital
City
Cannes
ZIP/Postal Code
06400
Country
France
Facility Name
Draguignan Hospital
City
Draguignan
ZIP/Postal Code
83300
Country
France
Facility Name
Frejus Hospital
City
Fréjus
ZIP/Postal Code
83600
Country
France
Facility Name
CHU de Nice
City
Nice
Country
France
Facility Name
Monaco princesse grace Hospital
City
Monaco
ZIP/Postal Code
98000
Country
Monaco

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Diagnostic Performance of a New Bio-marker During Bacterial Sepsis

We'll reach out to this number within 24 hrs